Aripiprazle in ADHD and ODD

Comparison of Risperidone and Aripiprazole as adjuvant Therapy in children with Atention deficit/hyperactivity disorder accopained by oppositional defiant disorder treated by Methylphenidate.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160530028182N5

Enrollment

Registered

2018-02-06

Start date

2018-02-03

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Attention deficit/hyperactivity disorder. Condition 2: oppositional Defiant Disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: A group of randomly selected patients received methylphenidate tablets (10 mg) for the first week (one quarter of the tablet at 8:00 am and one quarter of the table

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Age between 6 -12 years Diagnosis of ADHD and ODD based on DSM5 without effective medication taking on mental status at least 2 weeks before the study

Exclusion criteria

Exclusion criteria: Intelectual disability based on clinical suspicious presence of uncontroled siezure Drug side effects and hypersensivity Recieving of any other drugs History of psychological disorder except for ADHD and ODD presence of medical deasese such as cardiac deaseses

Design outcomes

Primary

Measure	Time frame
Improvment in Attention-deficit symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in Impulsivity symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in hyperactivation symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in behavioral symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.	—

Measure

Time frame

Improvment in Attention-deficit symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in Impulsivity symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in hyperactivation symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.;Improvment in behavioral symptoms. Timepoint: Baselin , second,fourth and eighth weeks after intervention. Method of measurement: Canner's and ADHD Rating scales.

—

Secondary

Measure	Time frame
Severity of ADHD symptoms. Timepoint: Baselin , second ,fourth and eighth weeks after intervention. Method of measurement: ADHD Rating scale and CGI.;?Drug Sideeffects. Timepoint: Baselin , second ,fourth and eighth weeks after intervention. Method of measurement: Sideeffects quessionners.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Soleiman Mohammadzadeh

Sanandaj University of Medical Sciences

dr.mohammadzadeh86@muk.ir+98 87 3366 4653

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026